# A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

> **NCT05751928** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 411 (actual)

## Conditions studied

- Melanoma Stage III
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** BCD-217
- **BIOLOGICAL:** anti-PD1
- **PROCEDURE:** Excision of the primary lesion
- **PROCEDURE:** Regional lymphadenectomy

## Key facts

- **NCT ID:** NCT05751928
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751928, "A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05751928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*